ClearPoint Neuro Secures $110 Million Investment from Oberland Capital
Deal News | May 12, 2025 | Oberland Capital Management LL
ClearPoint Neuro, Inc., a company specializing in device, cell, and gene therapy navigation, has garnered a significant financial commitment from Oberland Capital Management LLC. The deal, anchored by a $105 million note financing agreement with $30 million already disbursed, is further augmented by a $3.5 million direct equity placement. These funds, earmarked for corporate growth and development, will enable ClearPoint to accelerate product introductions, expand its infrastructure, and support ongoing clinical trials for its numerous pharmaceutical associates. Oberland's integration of equity, royalty, and debt financing seeks to champion ClearPoint's cutting-edge medical solutions aimed at previously unmet healthcare needs. Major firms such as Covington & Burling LLP and Cooley LLP provided legal counsel to the parties involved.
Sectors
- Healthcare Technology
- Private Equity
- Biotechnology
Geography
- United States – The investment deal involves ClearPoint Neuro, headquartered in California, and Oberland Capital, a U.S.-based private equity firm, signifying a domestic focus.
Industry
- Healthcare Technology – ClearPoint Neuro is engaged in developing medical technologies for brain and spinal navigation, contributing to this industry classification.
- Private Equity – Oberland Capital, as a private investment firm, categorizes the financial aspect of the deal within this industry.
- Biotechnology – ClearPoint's involvement in cell and gene therapy indicates relevance to the biotechnology sector.
Financials
- 110,000,000 – Total potential investment by Oberland Capital, including note financing and equity purchase.
- 30,000,000 – Initial funding amount provided by Oberland Capital at the closing of the deal.
- 3,500,003.52 – Proceeds from the direct purchase of 275,808 shares of ClearPoint Neuro's stock by Oberland Capital.
- 12.69 – The price per share paid by Oberland Capital based on a volume-weighted average.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ClearPoint Neuro, Inc. | Target | Company | A technology company specializing in device, cell, and gene therapy navigation solutions. |
| Oberland Capital Management LLC | Investor | Company | A U.S.-based private investment firm focused on the global healthcare industry. |
| Covington & Burling LLP | Legal Advisor for Note Financing | Company | Legal advisor to ClearPoint Neuro for the note financing components of the deal. |
| Sheppard, Mullin, Richter & Hampton LLP | Legal Advisor for Direct Offering | Company | Legal advisor to ClearPoint Neuro for the registered direct stock offering. |
| Cooley LLP | Legal Advisor to Oberland Capital | Company | Legal advisor to Oberland Capital for the investment transactions. |